EDAP TMS SA to Announce Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021
- Wall Street closes lower as virus spike hits travel stocks
- Netflix (NFLX) Tops Q1 EPS by 78c, Subs Miss
- Analysts Positive, Raise PTs as IBM (IBM) Tops Market Estimates and Reaffirms Guidance
- Boeing (BA) Down 3% After CFO - Aged 54 - Retires, Seen as an 'Odd' Move
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Company to host conference call and webcast on Wednesday, March 31 at 8:30 am EDT
LYON, France, March 23, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020 after the markets close on Tuesday, March 30, 2021.
An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, March 31, 2021. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Call & WebcastWednesday, March 31st @ 8:30am Eastern TimeDomestic: 877-451-6152International: 201-389-0879Passcode: 13717550Webcast: http://public.viavid.com/index.php?id=143913
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
Company ContactBlandine ConfortInvestor Relations / Legal AffairsEDAP TMS SA+33 4 72 15 31 firstname.lastname@example.org
Investor ContactJeremy FefferLifeSci Advisors, LLC212email@example.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Premier Financial (PFC) Tops Q1 EPS by 34c
- Reliq Health Technologies, Inc. Announces Two New Contracts with US Nephrology Clinics
- Origen Acquires Greenfield Lithium Targets in Newfoundland